TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Insomnia Severity Index Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fatty acid profile quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pro-inflammatory and Anti-inflammatory Cytokines profile in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Net reclassification index (NRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR 50 improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAS28 evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal Wall Composition: Epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Collagen Content in Vaginal Muscularis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal Wall Degradative Activity, Muscularis, MMP-9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of CTC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of skin rash in patients with acne
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Directional Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum tolerated dose of allogeneic DC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tonic-clonic seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Hip Outcome Score - ADL Subscale at 24 Months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Hip Outcome Score - Sport Subscale at 24 Months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of Patient Wanting Provider to Use QA-DDS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of Patient Wanting to Use QA-DDS Patient Portal
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of Patient Completion of 1-Month Follow-Up Survey
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in serum and CSF cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Positive Predictive Value of FACBC Compared to Histology to Detect Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Positive Predictive Value of FACBC to Detect Presence of Malignant Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: AUClast of proguanil, cycloguanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular target organ damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Degree of change in angle of vocal folds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of SSE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein levels in tear fluid, saliva and blood (plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Depression Scale (HAM-d)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical Global Impression- Change (CGI-C)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Psychologix and Cogscreen Test Batteries, RAVLT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in the prescription share of Flixovate®
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: NYHA Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AVA >= 0.65 cm2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arterial serum purine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HP eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pulsatility index on the middle cerebral arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diastolic velocity at the middle cerebral arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean velocity at the middle cerebral arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent of subjects with VZV specific antibody titre >= 5gp ELISA units/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MRI calculated kidney volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Muscle mass maintenance or increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Area Under the Time Concentration Curve (AUC0-12h) of Linezolid in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SVR at 12 Weeks After Discontinuation of Therapy (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: latency until delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: maximum tolerated dose of SU011248
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: response rate of SU011248
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent of expression progerin in follicular cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in anterior chamber inflammatory cells grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of serum TNF-alpha level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Emergency Department Visits due to Falls
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Efficacy of apremilast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GADD34 RNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slope of the Second Phase Decline in Plasma HCV RNA Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to low-dose aspirin
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Persistence to low-dose aspirin
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Capsaicin Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical cure rates at test of cure visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peri-operative or postoperative complication
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change in Serum Insulin-like Growth Factor-1 (IGF-1) From Baseline to 28 Days After Last Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change From Baseline in the Disease Activity Score (DAS28-CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum alanine aminotransferase (ALT) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change in magnetic resonance imaging-determined hepatic steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Measurement reliability index Magnin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity and frequency of upper abdominal and shoulder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence and frequency of AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Time of maximum concentration (Tmax) of PF-05089771 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment dropout
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mortality From Any Cause
Endpoint domain: Mortality/survival
Primary endpoint: First Heart Failure (HF) Event
Endpoint domain: Mortality/survival
Primary endpoint: Alcohol drinks per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability after single dose
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability after multiple doses
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnosis of ascites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to recovery from pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LBP symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of a cerebral lesion requiring surgery or medical intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Complete Healing of Corneal Epithelial Defect at Day 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Healing of Corneal Epithelial Defect at Day 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opacification of posterior capsule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5 years Survival
Endpoint domain: Mortality/survival
Primary endpoint: Successful completion of the operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in the Peri-implant Marginal Bone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Implant stability quotient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Gingival Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Acute GVHD Response at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of wound area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Clinical response assessed by GCSI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Post-intervention change in urinary 8-hydroxydeoxyguanosine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Post-intervention change in urinary 8-F2-isoprostanes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Extent of coronal dental caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of root dental caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma triglyceride and fatty acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SD1 Index of Heart Rate Variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cmax(0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tampon Test Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants who are without disease flare following the first dose of rilzabrutinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of SAE, AE leading to discontinuation and possible glucocorticoid-related AE
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with Potentially clinically significant abnormalities (PCSAs) for clinical laboratory tests, vital signs and ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain severity in the past week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of naproxen vs. placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MRF diagnostic power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Muscle strength of the lower limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in Body composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax and Area Under the Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to first postoperative bowel movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from baseline Fugl-Meyer Assessment (Upper extremity section) at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Box and Blocks Test at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline ABILHAND at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Formation Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hypoglycemia Episode Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: hs-Troponin elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUC of the plant based ingredient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined Incidence of Persistent HPV Infection or Related-Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Adverse Events/Serious Adverse Events (AEs/SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Postprandial increase plasma triglyceride concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adverse food reactions
Endpoint domain: Adverse events/effects
Primary endpoint: clinical efficacy of ATH1017
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Electrocardiogram (ECG): Ventricular rate (bpm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Index of Microvascular Resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Agreement Between TRUE Test Allergen and Reference Allergen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With 4-fold or Greater HAI Antibody Titer Increases Against H1N1 2009 Virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sero-conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in DASH score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Best Estimate Diagnosis of ADHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Growth rates categorization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Resting-state Functional Connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Task-based Functional Connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Surgeon's assessment of surgical field visual quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Lake Louise AMS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of time catheter remains in place without clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for hospital-based intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Safety of formulations
Endpoint domain: Adverse events/effects
Primary endpoint: Control of elevated intracranial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Migraine frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of Antidiabetic Medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Expression level of miR-185 in salivary exosomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression level of miR-185 in plasma exosomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Video Head Impulse Test (vHIT) results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caregiver Reaction Assessment (CRA) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Desflurane consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Infection rates associated with peri-implant microbiota
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of alopecia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Intraoperative and postoperative fentanyl requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early and sensitive diagnosis of Morquio disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sedentary behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in clozapine prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in prescriber knowledge of clozapine use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in self-reported competence for clozapine use
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Duration of motor block until return to normal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Adverse Events Within the 28 Day Follow-up
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Any Symptoms Reported During the 7-day Post Vaccination Period
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of General Symptoms Reported During the 7-day Post Vaccination Period
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Local Symptoms Reported During the 7-day Post Vaccination Period
Endpoint domain: Adverse events/effects
Primary endpoint: Summary of Subjects With Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Upper Extremity Motor Score (UEMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving PSA Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in DLQI at Week 12
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Severe PPH Defined as Blood Loss ≥1000 ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postpartum Laparotomy for Bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Postpartum Maternal Death From Bleeding
Endpoint domain: Mortality/survival
Primary endpoint: H-reflex and M-wave ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Force measurements of bimanual dexterity function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Biotin Labeled Red Blood Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: incident disability (mobility, ADL and IADL disability)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD-RS Total Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in ALSFRS-R from baseline to week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between acceleromyography and electromyography derived TOF ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Intra-abdominal Pressure (IAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-treatment biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of relapses of ocular inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction rate of number of acne lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to Maximal Circulating Tumor Cell Burden (CTCB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in CTCB From Baseline to Post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes